Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?
Publication
, Journal Article
Hurwitz, HI; Lyman, GH
Published in: J Clin Oncol
February 20, 2012
Duke Scholars
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
February 20, 2012
Volume
30
Issue
6
Start / End Page
580 / 581
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Medicare
- Male
- Humans
- Female
- Colorectal Neoplasms
- Bevacizumab
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Hurwitz, H. I., & Lyman, G. H. (2012). Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme? J Clin Oncol, 30(6), 580–581. https://doi.org/10.1200/JCO.2011.40.7031
Hurwitz, Herbert I., and Gary H. Lyman. “Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?” J Clin Oncol 30, no. 6 (February 20, 2012): 580–81. https://doi.org/10.1200/JCO.2011.40.7031.
Hurwitz HI, Lyman GH. Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme? J Clin Oncol. 2012 Feb 20;30(6):580–1.
Hurwitz, Herbert I., and Gary H. Lyman. “Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?” J Clin Oncol, vol. 30, no. 6, Feb. 2012, pp. 580–81. Pubmed, doi:10.1200/JCO.2011.40.7031.
Hurwitz HI, Lyman GH. Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme? J Clin Oncol. 2012 Feb 20;30(6):580–581.
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
February 20, 2012
Volume
30
Issue
6
Start / End Page
580 / 581
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Medicare
- Male
- Humans
- Female
- Colorectal Neoplasms
- Bevacizumab
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized
- 3211 Oncology and carcinogenesis